Weekly Market Movers (to 29 Mar 2013)

Source EP Vantage
Company Repros TherapeuticsHeron TherapeuticsAnGes MGARIAD PharmaceuticalsArray BioPharmaAstex PharmaceuticalsCadence PharmaceuticalsEndocyteGentiumGuangdong Zhongsheng PharmaceuticalHalozyme TherapeuticsHubei Guangji PharmaceuticalIdenix PharmaceuticalsKyung Dong PharmaceuticalNicoxOncoTherapy ScienceOsiris TherapeuticsPharmaxisRaQualia PharmaSarepta TherapeuticsSINOPHARMSucampo PharmaceuticalsThromboGenicsZIOPHARM Oncology 
Tags EventAnalyzer - Weekly, Free Content
Date April 01, 2013

EvaluatePharma’s EventAnalyzer delivers a weekly global round up of key events driving company valuations.

Detailing the previous week’s top 15 market gains and losses, aligned with significant news flow driving share prices, the EventAnalyzer keeps you in touch with the latest market moves.

Top 15 Gains (%) - ranked on change in share price

      Performance: Fri 29 Mar vs. Fri 22 Mar   
Rank  Company  Listed Currency  Share Price Change  Market Cap (US$m)  Market Cap Change  Notes on Change 
Repros Therapeutics   USD  +83%  300  +136  27 Mar [post market]: Company's key hypogonadism treatment, Androxal, meets both its co-primary endpoints in phase III trials. 
AnGes MG   JPY  +71%  335  +139  Shares rise on heavy volumes throughout the week, peaking at 8x average daily trading volume on 28 Mar. 
Gentium   EUR  +26%  126  +27  26 Mar: Company initiates phase I trials for its deep vein thrombosis treatment, Defibrotide, in Japan.
28 Mar: Company announces better-than-expected Q4'12 and FY'12 revenues, helped by higher sales of its deep vein thrombosis treatment, Defibrotide
Endocyte   USD  +24%  447  +87  27 Mar: Wedbush maintains "outperform" rating and raises price target to $20 from $16, stating that the company's cancer drugvintafolide, will likely receive EU approval for the treatment of ovarian cancer by the end of the year. 
RaQualia Pharma   JPY  +24%  181  +35  26 Mar: Shares rise on 3x average daily trading volume. 
Hubei Guangji Pharmaceutical   CNY  +21%  306  +54  Shares rise on heavy volumes throughout the week, peaking at 5.5x average daily trading volume on 28 Mar. 
Guangdong Zhongsheng Pharmaceutical   CNY  +19%  1141  +185  Shares rise on heavy volumes throughout the week, peaking at 3.5x average daily trading volume on 27 Mar. 
Cadence Pharmaceuticals   USD  +17%  573  +84  28 Mar: JMP Securities initiates coverage with "market outperform" rating and a price target of $8. 
Array BioPharma  USD  +14%  573  +73  25 Mar: Piper Jaffray upgrades rating to "overweight" from "neutral" and raises price target to $7 from $4, citing upcoming additional phase II data for  ARRY-520 in refractory multiple myeloma. 
10  Kyung Dong Pharmaceutical   KRW  +13%  228  +26  29 Mar: Shares rise on 2.5x average daily trading volume. 
11  GNI   JPY  +13%  456  +52   
12  Sarepta Therapeutics   USD  +13%  1176  +133  25 Mar: A report in Barron's financial newspaper states that shares of the company could rise swiftly, potentially reaching $50 per share if the company seeks accelerated US approval for its Duchenne muscular dystrophy, eteplirsen
13  Sucampo Pharmaceuticals   USD  +11%  446  +45  26 Mar: Shares rise on 2.5x average daily trading volume. 
14  OncoTherapy Science   JPY  +10%  715  +65  22 Mar: Shares rise on 2.5x average daily trading volume. 
15  Astex Pharmaceuticals   USD  +10%  418  +37  Shares rise on heavy volumes throughout the week, peaking at 5x average daily trading volume on 28 Mar. 

Excludes companies with a market cap. movement of less than US$25m.

Top 15 Losses (%) - ranked on change in share price

      Performance: Fri 29 Mar vs. Fri 22 Mar   
Rank  Company  Listed Currency  Share Price Change  Market Cap (US$m)  Market Cap Change  Notes on Change 
ZIOPHARM Oncology   USD  -62%  153  -253  26 Mar: Company abandons development of its lead cancer treatment, palifosfamide, after it fails to meet its main goal of improvement in progression-free survival in phase III trials. 
A.P. Pharma  USD  -40%  113  -78  28 Mar: The FDA rejects the company's chemotherapy-induced nausea and vomiting treatment, APF530, requesting re-analysis of existing phase III trial data and a human factors validation study evaluating the usability of its syringe system, potentially delaying the drug's launch to H1'14. 
Pharmaxis   AUD  -23%  107  -32  Shares fall on heavy volumes throughout the week, peaking at 5x average daily trading volume on 27 Mar. 
Idenix Pharmaceuticals   USD  -23%  474  -142  22 Mar [post market]: Company receives an unfavourable ruling from the USPTO regarding a patent dispute with Gilead Sciences covering certain compounds used in hepatitis C treatment, with  Gilead named as the first party to file for a patent application, making it unlikely that  Idenix will be declared the inventor and patent holder.
25 Mar: Bank of America  downgrades rating to "underperform" from "neutral", and lowers price target to $3 from $7. 
Halozyme Therapeutics   USD  -16%  652  -129  25 Mar: Shares fall on 4x average daily trading volume. 
Chiome Bioscience   JPY  -12%  456  -60   
NicOx   EUR  -10%  267  -29  22 Mar: Company reports FY'12 losses, hurt by rise in R&D costs and selling and administrative expenses. 
SINOPHARM   HKD  -8%  2676  -241  27 Mar [post market]: Company plans to raise $515m through the sale of 165.7 million shares at $3.16 per share, an 8.9% discount on company's closing share price on 27 Mar. 
Beijing Tiantan Biological Products (TiantanBio)   CNY  -7%  1292  -105   
10  Osiris Therapeutics  USD  -7%  342  -28  28 Mar: Shares fall on 2.5x average daily trading volume. 
11  ThromboGenics   EUR  -7%  1793  -137  26 Mar: Jefferies maintains "buy" rating and lowers price target to €53 from €56. 
12  Zhejiang Hisun Pharmaceutical   CNY  -7%  1980  -150   
13  Jiangxi Boya Bio-Pharmaceutical   CNY  -7%  413  -30   
14  ARIAD Pharmaceuticals   USD  -7%  3323  -239  28 Mar: Goldman Sachs initiates coverage with "neutral" rating and price target of $20, citing fair valuation. 
15  Ube Industries   JPY  -7%  2095  -148   

Excludes companies with a market cap. movement of less than US$25m.

Disclaimer:
The above analysis is based on daily share prices supplied to EvaluatePharma Ltd by a third party. EvaluatePharma Ltd accepts no responsibility or liability for the accuracy of the data presented here. Neither should any data presented here be construed as a solicitation or offer to buy or sell any securities or related financial instruments.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM
©2014 EP Vantage Ltd